{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:35:43Z","timestamp":1794198943968,"version":"4.8.0"},"reference-count":230,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AI163350"],"award-info":[{"award-number":["K23AI163350"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM144273"],"award-info":[{"award-number":["T32GM144273"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.anai.2023.01.018","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T07:03:09Z","timestamp":1674630189000},"page":"699-712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab"],"prefix":"10.1016","volume":"130","author":[{"given":"Tejas S.","family":"Athni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8188-9187","authenticated-orcid":false,"given":"Sara","family":"Barmettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0002","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: the first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo-L\u00f3pez","year":"2000","journal-title":"Curr Pharm Biotechnol"},{"issue":"11","key":"10.1016\/j.anai.2023.01.018_bib0004","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/archdischild-2020-321211","article-title":"Use of rituximab in paediatric nephrology","volume":"106","author":"Sinha","year":"2021","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0005","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0006","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of anti-B cell therapeutics in autoimmune neurological diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.anai.2023.01.018_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2022.113385","article-title":"Acquired B-cell deficiency secondary to B-cell-depleting therapies","volume":"511","author":"Blincoe","year":"2022","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.anai.2023.01.018_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763412","article-title":"COVID-19 in B Cell-depleted patients after Rituximab: a diagnostic and therapeutic challenge","volume":"12","author":"Furlan","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.anai.2023.01.018_bib0009","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0010","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera\u00ae)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.anai.2023.01.018_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.928062","article-title":"Secondary immune deficiency and primary immune deficiency crossovers: hematological malignancies and autoimmune diseases","volume":"13","author":"Ballow","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.anai.2023.01.018_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0013","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"Q J M"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0014","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.anai.2023.01.018_bib0015","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux","volume":"94","author":"Deshayes","year":"2019","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.anai.2023.01.018_bib0016","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.40937","article-title":"Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases","volume":"71","author":"Md Yusof","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0017","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/ehm.11.62","article-title":"Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms","volume":"4","author":"Tesfa","year":"2011","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0018","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach","year":"2010","journal-title":"Medicine"},{"issue":"47","key":"10.1016\/j.anai.2023.01.018_bib0019","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0020","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0021","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1074\/jbc.273.1.344","article-title":"Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment","volume":"273","author":"Deans","year":"1998","journal-title":"J Biol Chem"},{"issue":"20","key":"10.1016\/j.anai.2023.01.018_bib0022","doi-asserted-by":"crossref","first-page":"15073","DOI":"10.1074\/jbc.M701654200","article-title":"Structural basis for recognition of CD20 by therapeutic antibody rituximab *","volume":"282","author":"Du","year":"2007","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1016\/j.anai.2023.01.018_bib0023","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0024","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.4049\/jimmunol.1601473","article-title":"Antibody distance from the cell membrane regulates antibody effector mechanisms","volume":"198","author":"Cleary","year":"2017","journal-title":"J Immunol"},{"issue":"20","key":"10.1016\/j.anai.2023.01.018_bib0025","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1038\/sj.onc.1207336","article-title":"Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance","volume":"23","author":"Vega","year":"2004","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0026","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","article-title":"Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-\u03baB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis","volume":"65","author":"Jazirehi","year":"2005","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.anai.2023.01.018_bib0027","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1158\/0008-5472.CAN-03-3500","article-title":"Inhibition of the Raf-MEK1\/2-ERK1\/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab","volume":"64","author":"Jazirehi","year":"2004","journal-title":"Cancer Res"},{"issue":"42","key":"10.1016\/j.anai.2023.01.018_bib0028","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.1038\/sj.onc.1210448","article-title":"Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis","volume":"26","author":"Suzuki","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0029","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0030","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00277-004-0917-0","article-title":"Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells","volume":"83","author":"Stanglmaier","year":"2004","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0031","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10495-006-6314-5","article-title":"Caspase-independent killing of Burkitt lymphoma cell lines by rituximab","volume":"11","author":"Daniels","year":"2006","journal-title":"Apoptosis"},{"issue":"12","key":"10.1016\/j.anai.2023.01.018_bib0032","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.anai.2023.01.018_bib0033","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0034","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/sji.12070","article-title":"Humoral pattern recognition and the complement system","volume":"78","author":"Degn","year":"2013","journal-title":"Scand J Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0036","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3892\/ol.2014.2099","article-title":"Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells","volume":"17","author":"Li","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.anai.2023.01.018_bib0037","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab-the World's first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.anai.2023.01.018_bib0038","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/intimm\/dxs048","article-title":"High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between Fc\u03b3Rllla polymorphism","volume":"24","author":"Mishima","year":"2012","journal-title":"Int Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0039","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2007-02-074716","article-title":"NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0040","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.4049\/jimmunol.181.4.2916","article-title":"Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-Opsonized daudi cells is promoted by NK Cells and inhibited by monocytes due to Shaving","volume":"181","author":"Beum","year":"2008","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0041","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature","volume":"2","author":"Kaplan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0042","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jaci.2015.06.035","article-title":"Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab\u2014for how long?","volume":"136","author":"Barmettler","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0043","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 124","key":"10.1016\/j.anai.2023.01.018_bib0044","first-page":"188","article-title":"Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study","volume":"38","author":"Padoan","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"suppl 2","key":"10.1016\/j.anai.2023.01.018_bib0045","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2019-eular.3767","article-title":"AB0473 hypogammaglobulinemia and infections in rheumatologic patients treated with rituximab","volume":"78","author":"Fierro","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0046","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12969-019-0365-y","article-title":"Rituximab-associated hypogammaglobulinemia in pediatric patients with autoimmune diseases","volume":"17","author":"Khojah","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0047","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.12998\/wjcc.v7.i9.1021","article-title":"Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values","volume":"7","author":"Marzuillo","year":"2019","journal-title":"World J Clin Cases"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0048","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaip.2019.07.032","article-title":"Rituximab unveils hypogammaglobulinemia and immunodeficiency in children with autoimmune cytopenia","volume":"8","author":"Ottaviano","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0049","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jaci.2021.03.041","article-title":"Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients","volume":"148","author":"Labrosse","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0050","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/rheumatology\/keab626","article-title":"New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases","volume":"61","author":"Ong","year":"2022","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0051","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.anai.2023.01.018_bib0052","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.anai.2023.01.018_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0054","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","article-title":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study","volume":"48","author":"Boleto","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0055","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","article-title":"Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis","volume":"53","author":"Besada","year":"2014","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0056","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00467-021-05304-4","article-title":"Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome","volume":"37","author":"Inoki","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0057","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/rheumatology\/keaa617","article-title":"Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience","volume":"60","author":"Evangelatos","year":"2021","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0058","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/acr.22993","article-title":"Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: long-term effects on serum immunoglobulins","volume":"69","author":"Reddy","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0059","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/art.41938","article-title":"Hypogammaglobulinemia in rheumatoid arthritis patients treated with rituximab: should we switch biologics? Comment on the article by Fraenkel et\u00a0al","volume":"74","author":"Evangelatos","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0060","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics","volume":"51","author":"De La Torre","year":"2012","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.anai.2023.01.018_bib0061","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s10067-017-3848-6","article-title":"Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies","volume":"36","author":"Einarsson","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.anai.2023.01.018_bib0062","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0063","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"Van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102466","article-title":"Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia","volume":"19","author":"Kridin","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0065","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"Van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0066","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/1574892811666160129110614","article-title":"Incidence of profound hypogammaglobulinemia and infection rate in lymphoma patients following the combination of chemotherapy and rituximab","volume":"11","author":"Filanovsky","year":"2016","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0067","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1212\/NXI.0000000000000498","article-title":"Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders","volume":"5","author":"Marcinn\u00f2","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0068","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.anai.2021.10.028","article-title":"Hypogammaglobulinemia after rituximab therapy in children","volume":"128","author":"Newman","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0069","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00296-021-04847-x","article-title":"Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study","volume":"41","author":"Wade","year":"2021","journal-title":"Rheumatol Int"},{"issue":"7","key":"10.1016\/j.anai.2023.01.018_bib0070","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0071","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0072","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.autrev.2014.08.036","article-title":"Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature","volume":"13","author":"Levy","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0073","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s10157-020-01858-z","article-title":"Profound effect of post-rituximab mycophenolate mofetil administration for persistent hypogammaglobulinemia in young children with steroid-dependent nephrotic syndrome","volume":"24","author":"Fujinaga","year":"2020","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0074","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5414\/CN108835","article-title":"Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome","volume":"85","author":"Fujinaga","year":"2016","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0075","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/BOR.0000000000000272","article-title":"Suppression of normal immune responses after treatment with rituximab","volume":"28","author":"Kado","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0076","doi-asserted-by":"crossref","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.anai.2023.01.018_bib0077","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.anai.2023.01.018_bib0078","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.leukres.2015.10.013","article-title":"Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study","volume":"39","author":"De Angelis","year":"2015","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.anai.2023.01.018_bib0079","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/imt-2017-0178","article-title":"Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution","volume":"10","author":"Sacco","year":"2018","journal-title":"Immunotherapy"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0080","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/annonc\/mdl141","article-title":"High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication","volume":"17","author":"Cabanillas","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0081","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00007890-200201150-00019","article-title":"Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication","volume":"73","author":"Verschuuren","year":"2002","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0082","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood.V95.4.1502.004k40_1502_1505","article-title":"CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation","volume":"95","author":"Kuehnle","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0083","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bmt.1704307","article-title":"Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein\u2013Barr virus-associated lymphoproliferative disease","volume":"33","author":"Imashuku","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0084","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2141.2003.04446.x","article-title":"Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma","volume":"122","author":"Shimoni","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.anai.2023.01.018_bib0085","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0086","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood.V99.4.1486","article-title":"Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab","volume":"99","author":"Goldberg","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0087","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2005.05.282","article-title":"Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma","volume":"23","author":"Miles","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0088","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0609.2006.00693.x","article-title":"Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"77","author":"Nishio","year":"2006","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0089","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00467-019-04398-1","article-title":"Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome","volume":"35","author":"Parmentier","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0090","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.anai.2023.01.018_bib0091","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0092","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.seminhematol.2010.01.009","article-title":"Rituximab-associated neutropenia","volume":"47","author":"Dunleavy","year":"2010","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0093","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MOH.0b013e32834da987","article-title":"Neutropenia after rituximab treatment: new insights on a late complication","volume":"19","author":"Wolach","year":"2012","journal-title":"Curr Opin Hematol"},{"issue":"12","key":"10.1016\/j.anai.2023.01.018_bib0094","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1080\/10428194.2021.1948037","article-title":"Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity","volume":"62","author":"Shimony","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.41501","article-title":"Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease","volume":"73","author":"Zonozi","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0096","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/10428190500473113","article-title":"Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments","volume":"47","author":"Cattaneo","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0097","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/qjmed\/hcs015","article-title":"Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center","volume":"105","author":"Besada","year":"2012","journal-title":"Q J M"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0098","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000034","article-title":"Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and rituximab registry","volume":"1","author":"Salmon","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.anai.2023.01.018_bib0099","doi-asserted-by":"crossref","first-page":"211","DOI":"10.12659\/AJCR.892541","article-title":"Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment","volume":"16","author":"Reitblat","year":"2015","journal-title":"Am J Case Rep"},{"issue":"11","key":"10.1016\/j.anai.2023.01.018_bib0100","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3346\/jkms.2014.29.11.1493","article-title":"Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP","volume":"29","author":"Choi","year":"2014","journal-title":"J Korean Med Sci"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0101","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/annonc\/mdl393","article-title":"A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study","volume":"18","author":"Nitta","year":"2007","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0102","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1179\/1607845414Y.0000000188","article-title":"Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma","volume":"20","author":"Arai","year":"2015","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0103","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2169\/internalmedicine.48.1368","article-title":"Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab","volume":"48","author":"Hirayama","year":"2009","journal-title":"Intern Med"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0104","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/sj.bmt.1704467","article-title":"Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma","volume":"33","author":"Lemieux","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0105","first-page":"361","article-title":"High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation","volume":"89","author":"Cairoli","year":"2004","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0106","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.2009.25.0274","article-title":"Immunoglobulin G Fc receptor FcgammaRIIIa 158-V\/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma","volume":"28","author":"Weng","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0107","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ajh.21818","article-title":"Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor Fc\u03b3RIIIa 158 (V\/F) polymorphism","volume":"85","author":"Li","year":"2010","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0108","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1445-5994.2011.02587.x","article-title":"Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma","volume":"42","author":"Keane","year":"2012","journal-title":"Intern Med J"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0109","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S1083-8791(00)70028-0","article-title":"Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma","volume":"6","author":"Flinn","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.anai.2023.01.018_bib0110","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2019-121343","article-title":"Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseases","volume":"134","author":"Malpica Castillo","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.anai.2023.01.018_bib0111","first-page":"765","article-title":"Drug-induced neutropenia: a focus on rituximab-induced late-onset neutropenia","volume":"41","author":"Moore","year":"2016","journal-title":"P T"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0112","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.anai.2023.01.018_bib0113","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/ajh.21420","article-title":"Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma","volume":"84","author":"Lai","year":"2009","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0114","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3109\/10428194.2012.679266","article-title":"Late-onset neutropenia following primary treatment of diff use large B-cell lymphoma with rituximab-containing therapy","volume":"53","author":"Rozman","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0115","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0116","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/jcp.2009.068940","article-title":"Does rituximab aggravate pre-existing hypogammaglobulinaemia?","volume":"63","author":"Diwakar","year":"2010","journal-title":"J Clin Pathol"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102505","article-title":"Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: a meta-analysis","volume":"19","author":"Thery-Casari","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.anai.2023.01.018_bib0118","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/acr.23781","article-title":"Long-term safety of rituximab in rheumatoid arthritis: analysis from the sunstone registry","volume":"71","author":"Winthrop","year":"2018","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0119","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0120","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10428190902730219","article-title":"Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis","volume":"50","author":"Aksoy","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0121","article-title":"Rituximab as maintenance therapy for patients with follicular lymphoma","volume":"2","author":"Vidal","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"10.1016\/j.anai.2023.01.018_bib0122","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.anai.2023.01.018_bib0123","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1136\/ard.2008.101675","article-title":"Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients","volume":"68","author":"Genovese","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0124","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0126","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/10428190902782210","article-title":"Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy","volume":"50","author":"Ganjoo","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0127","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2141.2009.07748.x","article-title":"Enterovirus infection of neuronal cells post-rituximab","volume":"146","author":"Kiani-Alikhan","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2257.2006.00751.x","article-title":"Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab","volume":"28","author":"Padate","year":"2006","journal-title":"Clin Lab Haematol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0129","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1086\/345746","article-title":"Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment","volume":"36","author":"Quartier","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"12 Suppl","key":"10.1016\/j.anai.2023.01.018_bib0130","first-page":"ECR49","article-title":"Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine\/cyclophosphamide and rituximab for relapsed B cell lymphoma","volume":"91","author":"Hartmann","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0131","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ajh.20200","article-title":"Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy","volume":"77","author":"Isobe","year":"2004","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0132","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V96.3.1184.015k54_1184_1186","article-title":"Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab","volume":"96","author":"Sharma","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0133","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2141.2002.03778.x","article-title":"Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma","volume":"119","author":"Song","year":"2002","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0134","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00277-007-0397-0","article-title":"Rituximab therapy increased post-transplant cytomegalovirus complications in non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation","volume":"87","author":"Lee","year":"2008","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0136","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1399-0012.2009.01044.x","article-title":"Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients","volume":"24","author":"Levi","year":"2010","journal-title":"Clin Transpl"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0137","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CLM.2005.n.053","article-title":"Fatal West Nile virus infection after rituximab\/fludarabine\u2013induced remission for non-Hodgkin's lymphoma","volume":"6","author":"Mawhorter","year":"2005","journal-title":"Clin Lymphoma Myeloma"},{"issue":"7","key":"10.1016\/j.anai.2023.01.018_bib0138","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab-related viral infections in lymphoma patients","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0139","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23144","article-title":"Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia","volume":"112","author":"Del Poeta","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0140","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0141","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0609.2008.01101.x","article-title":"BK virus infection and neurologic dysfunctions in a patient with lymphoma treated with chemotherapy and rituximab","volume":"81","author":"Ferrari","year":"2008","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0142","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood-2002-04-1271","article-title":"Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody","volume":"100","author":"Matteucci","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0143","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0144","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study","volume":"3","author":"Avouac","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.anai.2023.01.018_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103358","article-title":"Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis","volume":"57","author":"Schiavetti","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0146","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry","volume":"80","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0147","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/BOR.0000000000000812","article-title":"Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease","volume":"33","author":"Sparks","year":"2021","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0148","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.16896","article-title":"Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature","volume":"190","author":"Tepasse","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0149","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.semarthrit.2020.06.013","article-title":"Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab","volume":"50","author":"Leipe","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12883-021-02218-4","article-title":"Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD","volume":"21","author":"Esmaeili","year":"2021","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0151","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0152","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3324\/haematol.12557","article-title":"Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy","volume":"93","author":"Targhetta","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0153","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00001813-200501000-00012","article-title":"Precore mutant hepatitis B reactivation after treatment with CHOP\u2013rituximab","volume":"16","author":"Zell","year":"2005","journal-title":"Anti Cancer Drugs"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0154","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s002770100346","article-title":"Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report","volume":"80","author":"Ng","year":"2001","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.anai.2023.01.018_bib0155","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/10428190500062932","article-title":"Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations","volume":"46","author":"Law","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"10.1016\/j.anai.2023.01.018_bib0156","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jama.2013.281115","article-title":"Increased HBV reactivation risk with ofatumumab or rituximab","volume":"310","author":"Mitka","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0157","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3026(18)30152-2","article-title":"Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review","volume":"5","author":"Lu","year":"2018","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1016\/j.anai.2023.01.018_bib0158","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0160","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/annrheumdis-2011-200719","article-title":"Campylobacter fetus infection in three rheumatoid arthritis patients treated with rituximab","volume":"71","author":"Meyer","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"10.1016\/j.anai.2023.01.018_bib0161","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.2169\/internalmedicine.1031-18","article-title":"Successful empiric therapy for postsplenectomy sepsis with Campylobacter fetus in an abattoir worker with follicular lymphoma","volume":"57","author":"Nakazawa","year":"2018","journal-title":"Intern Med"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0162","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14712598.2020.1727440","article-title":"Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study","volume":"20","author":"Russo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0163","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12879-020-4929-8","article-title":"Two-sided femoral Campylobacter jejuni osteomyelitis in a patient with acquired hypogammaglobulinemia: a case report","volume":"20","author":"Hartman","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0164","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3947\/ic.2020.52.3.415","article-title":"Recurrent campylobacter bacteremia as the first manifestation of hypogammaglobulinemia: a case report and literature review","volume":"52","author":"Gharamti","year":"2020","journal-title":"Infect Chemother"},{"issue":"8","key":"10.1016\/j.anai.2023.01.018_bib0165","first-page":"1683","article-title":"Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis","volume":"35","author":"Lutt","year":"2008","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.anai.2023.01.018_bib0166","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3201\/eid1411.080003","article-title":"Bacteremia caused by Mycobacterium wolinskyi","volume":"14","author":"Chen","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0167","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/ckj\/sfx038","article-title":"Infectious complications of rituximab therapy in renal disease","volume":"10","author":"Nixon","year":"2017","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0168","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/cid\/ciaa127","article-title":"Serious infectious events and immunoglobulin replacement therapy in patients with autoimmune disease receiving rituximab: a retrospective cohort study","volume":"72","author":"Stabler","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0169","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0170","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab","volume":"87","author":"Ennishi","year":"2008","journal-title":"Int J Hematol"},{"issue":"11","key":"10.1016\/j.anai.2023.01.018_bib0171","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3109\/10428190903258780","article-title":"Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma","volume":"50","author":"Katsuya","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0172","first-page":"496","article-title":"Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity","volume":"91","author":"Brusamolino","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0173","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.10564","article-title":"Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen","volume":"92","author":"Kolstad","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0174","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0609.2007.00994.x","article-title":"Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma","volume":"80","author":"Venhuizen","year":"2008","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1399-3062.2008.00345.x","article-title":"Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient","volume":"11","author":"Kumar","year":"2009","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1016\/j.anai.2023.01.018_bib0176","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1440-1797.2009.01168.x","article-title":"Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection","volume":"14","author":"Shelton","year":"2009","journal-title":"Nephrology"},{"issue":"8","key":"10.1016\/j.anai.2023.01.018_bib0177","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/rheumatology\/ken234","article-title":"Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis","volume":"47","author":"Teichmann","year":"2008","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.anai.2023.01.018_bib0178","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome\u2014a retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0179","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00277-006-0206-1","article-title":"Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura","volume":"86","author":"Fianchi","year":"2007","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0180","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0181","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.mycmed.2012.12.049","article-title":"Cryptococcose osseuse chez une patiente porteuse d'une leuc\u00e9mie lymphocytique trait\u00e9e par fludarabine-cyclophosphamide-rituximab","volume":"23","author":"Ettahar","year":"2013","journal-title":"J Mycol Med"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0182","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/525852","article-title":"Persistent and relapsing babesiosis in immunocompromised patients","volume":"46","author":"Krause","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0183","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamainternmed.2013.374","article-title":"Cerebral toxoplasmosis after rituximab therapy","volume":"173","author":"Safa","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0184","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.diagmicrobio.2012.11.003","article-title":"Acanthamoeba encephalitis in a patient with systemic lupus treated with rituximab","volume":"75","author":"Alkhunaizi","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0185","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10067-014-2509-2","article-title":"Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab","volume":"33","author":"Heusele","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0186","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0609.2008.01165.x","article-title":"Risk factors for infection in haematology patients treated with rituximab","volume":"82","author":"Kanbayashi","year":"2009","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0187","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-021-01037-3","article-title":"Long-term safety of rituximab (risks of viral and opportunistic infections)","volume":"23","author":"Varley","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.anai.2023.01.018_bib0188","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1471-2334-13-317","article-title":"Infections in patients taking rituximab for hematologic malignancies: two-year cohort study","volume":"13","author":"Lanini","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0189","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1136\/annrheumdis-2020-217549","article-title":"Rituximab for granulomatosis with polyangiitis in the pandemic of Covid-19: lessons from a case with severe pneumonia","volume":"80","author":"Guilpain","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.anai.2023.01.018_bib0190","article-title":"POS1178 prescribing rituximab in patients with auto-immune diseases and acquired hypogammaglobulinemia: description of the risk of severe infection in 121 patients before the SARS-Cov2 era","volume":"81","author":"Xavier","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0191","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0192","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0193","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10428190802688509","article-title":"Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study","volume":"50","author":"Eve","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0194","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.anai.2023.01.018_bib0195","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/cncr.22666","article-title":"Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials","volume":"109","author":"Rafailidis","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0196","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0197","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"issue":"23","key":"10.1016\/j.anai.2023.01.018_bib0198","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1002\/cncr.25332","article-title":"Risk of mortality in patients with cancer who experience febrile neutropenia","volume":"116","author":"Lyman","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0199","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.anai.2023.01.018_bib0200","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.201700193","article-title":"Monitoring neutropenia for cancer patients at the point of care","volume":"1","author":"Inan","year":"2017","journal-title":"Small Methods"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0201","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0202","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"Van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0203","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1203475418811335","article-title":"Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies","volume":"23","author":"Papp","year":"2019","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0204","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5152\/eurjrheum.2016.16100","article-title":"Vaccination recommendations for adult patients with rheumatic diseases","volume":"3","author":"Tanr\u0131\u00f6ver","year":"2016","journal-title":"Eur J Rheumatol Inflamm"},{"key":"10.1016\/j.anai.2023.01.018_bib0205","unstructured":"Centers for Disease Control and Prevention. ACIP General Best Practice Guidelines for Immunization. 2021. Available at: https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/index.html. Accessed December 23, 2022."},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0206","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0207","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0208","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.01.018_bib0209","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S1081-1206(10)60572-8","article-title":"Assessment and clinical interpretation of polysaccharide antibody responses","volume":"99","author":"Paris","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/mdr.1997.3.125","article-title":"Epidemiology of pneumococcal serotypes and conjugate vaccine formulations","volume":"3","author":"Butler","year":"1997","journal-title":"Microb Drug Resist"},{"issue":"12","key":"10.1016\/j.anai.2023.01.018_bib0211","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJM199503233321201","article-title":"A population-based serologic survey of immunity to tetanus in the United States","volume":"332","author":"Gergen","year":"1995","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0212","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0213","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/cei.13024","article-title":"B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets","volume":"190","author":"Becerra","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.01.018_bib0214","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/art.40410","article-title":"Switched memory B cells are increased in oligoarticular and polyarticular juvenile idiopathic arthritis and their change over time is related to response to tumor necrosis factor inhibitors","volume":"70","author":"Marasco","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.anai.2023.01.018_bib0215","article-title":"Autoimmune cytopenias and dysregulated immunophenotype act as warning signs of inborn errors of immunity: results from a prospective study","volume":"12","author":"Schiavo","year":"2021","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.anai.2023.01.018_bib0216","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1007\/s10875-008-9182-7","article-title":"Autoimmune manifestations in common variable immunodeficiency","volume":"28","author":"Cunningham-Rundles","year":"2008","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0217","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jaci.2017.05.024","article-title":"Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry","volume":"141","author":"Mayor","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0218","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clim.2009.05.001","article-title":"Granulomatous disease in common variable immunodeficiency","volume":"133","author":"Ardeniz","year":"2009","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0219","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","article-title":"International consensus document (ICON): common variable immunodeficiency disorders","volume":"4","author":"Bonilla","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.anai.2023.01.018_bib0220","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/brainsci10100758","article-title":"Anti-CD20 agents for multiple sclerosis: spotlight on ocrelizumab and ofatumumab","volume":"10","author":"Florou","year":"2020","journal-title":"Brain Sci"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0221","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anai.2023.01.018_bib0222","first-page":"51","article-title":"Ofatumumab: a novel monoclonal anti-CD20 antibody","volume":"3","author":"Lin","year":"2010","journal-title":"Pharmgenomics Pers Med"},{"issue":"2","key":"10.1016\/j.anai.2023.01.018_bib0223","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel Type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.anai.2023.01.018_bib0224","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/10781552211073575","article-title":"Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma","volume":"28","author":"Davis","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"10.1016\/j.anai.2023.01.018_bib0225","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/13524585211047223","article-title":"Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u2a7e4 years in the N-MOmentum trial","volume":"28","author":"Rensel","year":"2022","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.anai.2023.01.018_bib0226","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.autrev.2015.07.013","article-title":"The mechanistic impact of CD22 engagement with epratuzumab on B cell function: implications for the treatment of systemic lupus erythematosus","volume":"14","author":"D\u00f6rner","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.anai.2023.01.018_bib0227","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cytogfr.2021.11.004","article-title":"B cell-activating factor and its targeted therapy in autoimmune diseases","volume":"64","author":"Zhang","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.anai.2023.01.018_bib0228","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"26","key":"10.1016\/j.anai.2023.01.018_bib0229","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2023.01.018_bib0230","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.anai.2023.01.018_bib0231","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062300042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062300042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:32:30Z","timestamp":1761053550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108112062300042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":230,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S108112062300042X"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2023.01.018","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2023.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}